Navigation Links
CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies today presented a poster abstract at the 43rd American Society of Clinical Oncology (ASCO) Annual meeting. The poster, entitled "Preliminary Results of a Phase 1 Clinical Trial of CYT-6901," announced the preliminary data of a National Cancer Institute conducted and CytImmune Sciences sponsored Phase 1 trial of CYT-6091 (Aurimune), CytImmune's lead drug compound. The Phase 1 clinical trial was designed to investigate whether: (1) Aurimune will perform identically in humans as it did in preclinical studies and companion animals and (2) the fever side effect observed in preclinical studies can be easily managed and separated from hypotension - the dose limiting side effect of the active pharmaceutical ingredient.

"This is a tremendous opportunity for CytImmune," said Dr. Lawrence Tamarkin. "Presenting preliminary Phase 1 trial results to the leading body of international oncology experts helps pave the way for nanomedicines as the next generation of targeted cancer therapies and their use in improving the biodelivery of potent, but highly toxic therapeutics. We believe CYT-6091 has the potential to become a new, versatile therapeutic which may be used to treat a broad spectrum of solid tumors."

CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer PEGylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities.

To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby av
'"/>




Page: 1 2 3

Related medicine technology :

1. CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ), a ... will present an overview of the company at the 13th annual ... Waldorf Astoria Hotel, Tuesday, February 15, 2011 at 11:30 a.m. Eastern ... days and may be accessed at www.wafergen.com . ...
... Ill., Feb. 2, 2011 Hospira, Inc. (NYSE: ... company, today reported results for the fourth quarter and full ... 2010, net sales were $992 million, and adjusted* diluted earnings ... $3.9 billion, and adjusted* diluted earnings per share were $3.31. ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2Hospira Reports Fourth-Quarter and Full-Year 2010 Results 2Hospira Reports Fourth-Quarter and Full-Year 2010 Results 3Hospira Reports Fourth-Quarter and Full-Year 2010 Results 4Hospira Reports Fourth-Quarter and Full-Year 2010 Results 5Hospira Reports Fourth-Quarter and Full-Year 2010 Results 6Hospira Reports Fourth-Quarter and Full-Year 2010 Results 7Hospira Reports Fourth-Quarter and Full-Year 2010 Results 8Hospira Reports Fourth-Quarter and Full-Year 2010 Results 9Hospira Reports Fourth-Quarter and Full-Year 2010 Results 10Hospira Reports Fourth-Quarter and Full-Year 2010 Results 11Hospira Reports Fourth-Quarter and Full-Year 2010 Results 12Hospira Reports Fourth-Quarter and Full-Year 2010 Results 13Hospira Reports Fourth-Quarter and Full-Year 2010 Results 14Hospira Reports Fourth-Quarter and Full-Year 2010 Results 15Hospira Reports Fourth-Quarter and Full-Year 2010 Results 16Hospira Reports Fourth-Quarter and Full-Year 2010 Results 17Hospira Reports Fourth-Quarter and Full-Year 2010 Results 18Hospira Reports Fourth-Quarter and Full-Year 2010 Results 19
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... workers has suggested that the workplace may play// an important ... current study examined the role of occupational workplace and the ... physical activity and irregular food intake are some of the ... seeing a rise in the occurrence of some of the ...
... In a unique initiative a railway station – Ongole town ... announcement system to not only broadcast arrival and departures of ... the need for safe sex. Andhra Pradesh in India has ... 50-year-old porter "The current generation is racing towards HIV/AIDS like ...
... whose mothers during pregnancy consumed// low-mercury fish couple of ... those mothers who did not. ,Conversely it ... mercury content lowered the intelligence score. ,The study ... intake of their mothers during pregnancy. ,Data revealed ...
... end-stage lung cancer who were given Tarceva lived longer than ... common cancer occurring both in men and women. Two studies ... from all over the world. ,The first study was ... conducted his study in 482 patients. The study was done ...
... of sleeping less may be due to other reasons// than age ... that had been associated with increased age for the elderly population ... findings of the research show that there may be other factors ... the geriatric people. ,The research findings point to five ...
... effective in detecting blocked// carotid artery that may increase ... Virginia Commonwealth University School of Dentistry have reported that ... health of the patient can show some cases of ... patient. ,The dentists to observe the entire ...
Cached Medicine News:Health News:Drug Tarceva for End-stage Lung cancer 2
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
... Catheter system is a technically ... external CSF drainage which reduces ... tube surfaces. Treated with the ... it reduces the potential for ...
Cruchfield Skull Traction Tong, small pattern....
Medicine Products: